Answers are grounded in this paper and cite their sources.
In December 2025, the Food and Drug Administration assessed and qualified the first artificial intelligence (AI)-powered tool for use in drug development trials; this AI system evaluates digital liver biopsies for steatohepatitis and fibrosis. However, AI is still being investigated before it can be applied directly to patient care in the field of Hepatology. Current patient-facing applications at most institutions are limited to assistive tools such as computer-aided polyp detection and large language model documentation tools that draft clinic notes and patient communications, although there exist radiographic and pathologic liver AI tools that could function at and may even exceed human capabilities. This review provides a broad introduction to AI and highlights clinical research that use AI to enhance the diagnosis, prognostication, and management of liver diseases. It will also discuss the challenges that will need to be overcome before AI can be adopted to clinical practice.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: